Non-Injectable Insulin Sales to Surge at 9.50% CAGR by 2034, Fueled by R&D and Innovation | Future Market Insights, Inc

The non-injectable insulin market is projected to generate US$ 1372.9 million in 2024. According to projections, the market will reach US$ 4,418.70 million in 2034. Between 2023 and 2033, the market is expected to register a CAGR of 9.50%.  Pharmaceutical companies and researchers strive to offer more convenient alternatives to traditional insulin injections, the market for non-injectable insulin has seen notable growth in recent years. With products like Afrezza, inhaled insulin offers needle-free administration, so it has been gaining attention for enhancing treatment adherence.

The non-injectable insulin market is projected to generate US$ 1372.9 million in 2024. According to projections, the market will reach US$ 4,418.70 million in 2034. Between 2023 and 2033, the market is expected to register a CAGR of 9.50%.  Pharmaceutical companies and researchers strive to offer more convenient alternatives to traditional insulin injections, the market for non-injectable insulin has seen notable growth in recent years. With products like Afrezza, inhaled insulin offers needle-free administration, so it has been gaining attention for enhancing treatment adherence.

Empower Informed Decision-Making: Preview Our Comprehensive Non-Injectable Insulin Market Research Report Before You Buy

As insulin is easy to administer, enzyme degradation may challenge its advancement, but new formulations and protective technologies are helping to address this issue. With advancements in skin permeability, transdermal insulin delivery is becoming a less invasive option. Long-term safety and efficacy are being refined for implantable insulin delivery devices.

Regulatory approvals and clinical trials of non-injectable insulin are poised to grow the market substantially, making it easier for diabetics to manage their condition. Healthcare stakeholders, who expect a significant impact on diabetes management, are closely monitoring these developments. The FDA approved a new emergency hypoglycemia treatment, Baqsimi. Individuals four years and older can receive this treatment, a powder administered through the nose. The United States has approved injectable glucagon for several decades. It was the first non-injectable glucagon product that was available.

A speaker at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease said there are several new ways diabetes patients could manage their condition through non-injectable insulin delivery. According to a speaker, oral insulin formulation could become a reality soon. The FDA approved Semaglutide (Rybelsus, Novo Nordisk) in September for treating type 2 diabetes without injections. Several large trials showed that this therapy reduced HbA1c significantly compared to placebo in several large trials. In addition to empagliflozin, sitagliptin, and empagliflozin, the oral SGLT2 inhibitor was demonstrated to reduce HbA1c significantly.

Non-injectable Insulin Market Research Report Coverage: 2024-2034

Western Europe

Eastern Europe

South Asia and Pacific

East Asia

The Middle East & Africa

Region

Brazil

Mexico

Germany

The United Kingdom

France

Spain

Poland

Czech Republic

Romania

India

Bangladesh

Australia

Japan

South Korea

GCC countries

South Africa

Israel

Eli Lilly

MannKind Corporation

Biocon

Oramed Pharmaceuticals

Dance Biopharm

Medtronic

Dance Biopharm

Senseonics

Bigfoot Biomedical

Understand global, regional, and country-level parameters with growth opportunities, historical data (2019-2023), and forecasts (2024-2034). Buy this report today!

Key Takeaways

"Research and development activities in the healthcare sector have increased. A combination of new technologies and studies will increase the demand for non-injectable insulins on the market," says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.).

Competitive Landscape

A high level of fragmentation characterizes non-injectable insulin management owing to multiple participants. Patients with diabetes have benefited from technology.

Purchase this report now to get key companies with their Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis.

More Valuable Insights Available

Future Market Insights offers an unbiased global market analysis, providing historical data for 2019 to 2023 and forecast statistics from 2024 to 2034.

To understand opportunities in the non-injectable insulin market, the market is segmented based on Dosage (Oral Pills, Sprays, Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Drug Stores), and Region (North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, Middle East, and Africa).

About the Healthcare Division at Future Market Insights

The healthcare team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations with the objective of providing authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends, including competitive landscape, profit margin, and research development efforts.

About the Author:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

Explore FMI's Extensive Coverage in the Healthcare Domain:

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the United Kingdom, the United States, and India. FMI's latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition.

Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us
Nandini Singh Sawlani   
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Logo: https://mma.prnewswire.com/media/1197648/3531122/FMI_Logo.jpg 

 

View original content:https://www.prnewswire.co.uk/news-releases/non-injectable-insulin-sales-to-surge-at-9-50-cagr-by-2034--fueled-by-rd-and-innovation--future-market-insights-inc-301996529.html